| Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. | |
| | |
MedLine Citation:
|
PMID: 10029077 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The natural history of hereditary and BRCA1- and BRCA2-associated epithelial ovarian cancer may differ from that of sporadic disease. The purpose of this study was to compare the clinical characteristics of BRCA1- and BRCA2-associated hereditary ovarian cancer, hereditary ovarian cancer with no identified BRCA1/2 mutation, and ovarian cancer in population-based controls. BRCA1 and BRCA2 mutation testing was carried out on index cases from 119 families with site-specific epithelial ovarian cancer or breast-ovarian cancer. We estimated overall survival in 151 patients from 57 BRCA1 and BRCA2 mutation families and compared it with that in 119 patients from 62 families in which a BRCA1/2 mutation was not identified. We compared clinical outcome and data on tumor histopathology, grade, and stage. We also compared survival in familial epithelial ovarian cancer, whether or not a mutation was identified, with that of an age-matched set of population control cases. Overall survival at 5 years was 21% (95% confidence interval, 14-28) in cases from BRCA1 mutation families, 25% (8-42) in BRCA2 mutation families, and 19% (12-26) in families with no identified mutation (P = 0.91). Survival in familial ovarian cancer cases as a whole was significantly worse than for population controls (P = 0.005). In the familial cases, we found no differences in histopathological type, grade, or stage according to mutation status. Compared to population control cases, mucinous tumors occurred less frequently in the familial cases (2 versus 12%, P<0.001), and a greater proportion of the familial cases presented with advanced disease (83% stage III/IV versus 56%; P = 0.001). We have shown that survival in familial ovarian cancer cases is worse than that in sporadic cases, whether or not a BRCA1/2 mutation was identified, perhaps reflecting a difference in biology analogous to that observed in breast cancer. |
| | |
Authors:
|
P D Pharoah; D F Easton; D L Stockton; S Gayther; B A Ponder |
Related Documents
:
|
7829067 - Localization of the vhr phosphatase gene and its analysis as a candidate for brca1. 15955237 - Haploinsufficiency for brca1 is associated with normal levels of dna nucleotide excisio... 9296497 - Arrest of the cell cycle by the tumour-suppressor brca1 requires the cdk-inhibitor p21w... 16246487 - Disruption of the fanconi anemia/brca pathway in sporadic cancer. 17174467 - Seasonality of serum prostate-specific antigen levels: a population-based study. 17698107 - Lead time of prostate cancer detected in population based screening for prostate cancer... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer research Volume: 59 ISSN: 0008-5472 ISO Abbreviation: Cancer Res. Publication Date: 1999 Feb |
Date Detail:
|
Created Date: 1999-03-04 Completed Date: 1999-03-04 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 2984705R Medline TA: Cancer Res Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 868-71 Citation Subset: IM |
Affiliation:
|
Department of Oncology, University of Cambridge Strangeways Research Laboratories, Wort's Causeway, United Kingdom. paul.pharoah@srl.cam.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
BRCA2 Protein Female Genes, BRCA1* Humans Middle Aged Neoplasm Proteins / genetics* Neoplasms, Glandular and Epithelial / genetics*, mortality Ovarian Neoplasms / genetics*, mortality Survival Rate Transcription Factors / genetics* |
| Chemical | |
Reg. No./Substance:
|
0/BRCA2 Protein; 0/Neoplasm Proteins; 0/Transcription Factors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced o...
Next Document: Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineere...